AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15987849
Drug: Calcium phosphate
RxNorm normalized name: Calcium Phosphate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium phosphate supplementation (CaP; 1.0 g elemental calcium)
Trial: 12721265
Drug: BMS-247550 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-247550 at a dose of 6 mg/m2/d administered as a 1-hour intravenous infusion daily for 5 consecutive days every 21 days
Trial: 12721265
Drug: BMS-247550 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-247550 at a dose of 8 mg/m2/d with filgrastim support
Trial: 12721265
Drug: BMS-247550 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-247550 at a dose of 6 mg/m2/d
Trial: 25491299
Drug: Intravitreal autologous
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal autologous CD34+ BM cell therapy
Trial: 22208833
Drug: Weekly spaced
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly spaced education e‐mails with content designed to improve teaching skills (group A)
Trial: 20595285
Drug: Anti-TNF inhibitors
RxNorm normalized name: anti-inhibitor coagulant complex
DrugBank: Anti-inhibitor coagulant complex (DB13151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF inhibitors (exact type not specified)
Trial: 7770402
Drug: Calcium nadroparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium nadroparin (0.3 ml daily, 3075 anti-Xa IU)
Trial: 7770402
Drug: Calcium heparin
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium heparin (0.2 ml-5000 UI if <70 kg or 0.3 ml-7500 IU if ≥70 kg, twice a day)
Trial: 2182705
Drug: Rifampin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (300 mg daily for 2 weeks)
Trial: 2182705
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily for 2 weeks)
Trial: 44234
Drug: Thiazide diuretic
RxNorm normalized name: Thiazide diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide diuretic treatment
Trial: 44234
Drug: Other drug
RxNorm normalized name: Other drugs for bile therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other drug treatment
Trial: 44234
Drug: Beta-adrenoreceptor-blocking drugs
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenoreceptor-blocking drugs (suggested therapy)
Trial: 29672935
Drug: Hawthorn (Crataegus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hawthorn (Crataegus oxyacantha) 160 mg
Trial: 27147610
Drug: IC adenosine
RxNorm normalized name: Cyclic adenosine monophosphate
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IC adenosine (2-3 mg total)
Trial: 27147610
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (500 μg total)
Trial: 24599772
Drug: Exercise programme
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise programme with leucine supplementation (10 g/day)
Trial: 22465904
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg/d) plus zinc (440 mg/d)
Trial: 24115188
Drug: Fluoxetine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine plus placebo
Trial: 19293160
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) 50 mg once weekly plus methotrexate (MTX)
Trial: 18035427
Drug: CIPRODEX Otic
RxNorm normalized name: Ciprodex Otic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIPRODEX Otic Suspension (CIP/DEX) - four drops instilled into each middle ear through tympanostomy tubes
Trial: 16101608
Drug: 600 microg
RxNorm normalized name: Fentanyl 600 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 microg oral misoprostol
Trial: 16101608
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with four 0.5-mg ergometrine tablets
Trial: 12808615
Drug: Octreotide in
RxNorm normalized name: octreotide Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide in combination with IFN-alpha
Trial: 1602956
Drug: Mannitol (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol (250 cc intravenous at 20% injected in 1 h)
Trial: 1602956
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (intravenous perfusion glucose serum 250 cc with 1 g of vitamins C, 250 mg of vitamin B6 and 1 g of calcium gluconate injected in 1 h)
Trial: 3902523
Drug: Human chorionic
RxNorm normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human chorionic gonadotropin (hCG) administered intramuscularly, initial dosage of 10,000 IU followed by 5,000 IU twice weekly up to week 12, then once weekly up to week 16
Trial: 28581284
Drug: Topical mydriatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mydriatic
Trial: 24809882
Drug: Clocortolone pivalate
RxNorm normalized name: Clocortolone Pivalate
DrugBank: Clocortolone (DB00838)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clocortolone pivalate cream 0.1% (Cloderm Cream, Promius Pharma)
Trial: 24809882
Drug: Hydrocortisone butyrate
RxNorm normalized name: Hydrocortisone Butyrate
DrugBank: Hydrocortisone butyrate (DB14540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone butyrate lotion
Trial: 22869562
Drug: GS-9451 60
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-9451 60 mg once daily
Trial: 22869562
Drug: GS-9451 200
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-9451 200 mg
Trial: 22869562
Drug: GS-9451 400
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-9451 400 mg
Trial: 22869562
Drug: GS-9451 200
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-9451 200 mg and 400 mg
Trial: 15668859
Drug: Intravenous dalbavancin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dalbavancin (1000 mg single dose followed by 500 mg one week later)
Trial: 15668859
Drug: Intravenous vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous vancomycin (administered twice daily for 14 days)
Trial: 11886001
Drug: Weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel 35 mg/m2, gemcitabine 800 mg/m2 and cisplatin 35 mg/m2, on days 1 and 8 every 3 weeks
Trial: 11886001
Drug: Weekly docetaxel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel, gemcitabine and cisplatin
Trial: 7498206
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg
Trial: 7641363
Drug: Losartan-Captopril combination
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan-Captopril combination
Trial: 8061848
Drug: Spirapril 12
RxNorm normalized name: spirapril 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirapril 12 mg once daily
Trial: 9711470
Drug: Nitrendipine 20
RxNorm normalized name: nitrendipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine 20 mg once daily
Trial: 2238185
Drug: Hydrochlorthiazide 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorthiazide 12.5 mg daily (as a supplement to spirapril)
Trial: 2238185
Drug: Hydrochlorthiazide (as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorthiazide (as a supplement to nitrendipine)
Trial: 22444187
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline pretreatment
Trial: 15450054
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of antipsychotic medications
Trial: 15450054
Drug: Continued treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued treatment with antipsychotic medications
Trial: 11588698
Drug: Caspofungin 50
RxNorm normalized name: caspofungin 50 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin 50 mg/day
Trial: 11588698
Drug: Caspofungin 70
RxNorm normalized name: caspofungin 70 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin 70 mg/day
Trial: 9870832
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B 0.5 mg/kg/day
Trial: 7916274
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (beta-blocker therapy)
Trial: 2688346
Drug: Ranitidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (50 mg IV every 6 hours for 8 days)
Trial: 472340
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg 15‐methyl‐PGF2 alpha methyl ester
Trial: 472340
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg 15‐methyl‐PGF2 alpha methyl ester
Trial: 472340
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration of 15‐methyl‐PGF2 alpha methyl ester
Trial: 30878222
Drug: Ivermectin (150-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (150-200 μg/kg) and albendazole (400 mg) plus five further doses of ivermectin alone at 3-week intervals over 18 weeks
Trial: 30878222
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received single oral doses of ivermectin (150-200 μg/kg) and albendazole (400 mg) without further doses of ivermectin
Trial: 23338110
Drug: bupivacaine 8.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 8.0 mg + clonidine 75 µg + morphine 100 µg
Trial: 23338110
Drug: bupivacaine 10
RxNorm normalized name: BUPivacaine 100 mg parenteral implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 10 mg + clonidine 75 µg + morphine 100 µg
Trial: 20625342
Drug: Hypothermia therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermia therapy (32.5°C) for 24 hours, started within 8 hours of injury and rewarming at a rate of 0.5°C every 2 hours
Trial: 20625342
Drug: Serum GFAP
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum GFAP cutoff level of 0.6 ng/mL
Trial: 18025525
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg bid voriconazole
Trial: 18025525
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg qd efavirenz
Trial: 14987322
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg b.d. plus dietary treatment
Trial: 9270067
Drug: Acentrally active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acentrally active drug that enhances AMPA receptor‐mediated currents
Trial: 30742718
Drug: Prenatal exposure
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal exposure to asthma medications among mothers with asthma
Trial: 24747626
Drug: Topical glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glyceryl trinitrate (GTN) patches applied once a day
Trial: 23285271
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ISG and ITP (ITP+ISG)
Trial: 20584114
Drug: Nicardipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (10 mg diluted in 10 mL of distilled water daily, N=37)
Trial: 20584114
Drug: Control (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (10 mL of saline water, N=37)
Trial: 17356786
Drug: Adjustable medication
RxNorm normalized name: DEPEND ADJUSTABLE,MAXIMUM SM/MED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjustable medication dosing
Trial: 17356786
Drug: Fixed medication
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed medication dosing
Trial: 15365685
Drug: Intravenous citalopram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous citalopram (10 mg, 20 mg, 40 mg, 0.33 mg/kg)
Trial: 12166339
Drug: Incadronate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incadronate (10 mg intravenous infusion)
Trial: 12166339
Drug: Elcatonin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elcatonin (40 IU intramuscular injections twice daily for 7 days)
Trial: 7791151
Drug: Salsalate 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salsalate 3.0 g/day (titrated to 3.55 g/day)
Trial: 7791151
Drug: Diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 75 mg/day (titrated to 112 mg/day)
Trial: 1983322
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg nizatidine b.d.
Trial: 2570012
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg nizatidine nocte
Trial: 583489
Drug: Preparation A
RxNorm normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation A (Digacin)
Trial: 2631854
Drug: Preparation B
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation B
Trial: 2631854
Drug: Preparation C
RxNorm normalized name: other nasal preparation combinations in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation C
Trial: 583489
Drug: Preparation D
RxNorm normalized name: Digitalis preparation Delayed Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation D
Trial: 30423462
Drug: Inflammatory stress
RxNorm normalized name: Arthriten Inflammatory Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inflammatory stress (Salmonella typhi vaccine)
Trial: 24352094
Drug: 7% carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7% carbohydrate (CHO) solution (700 mL)
Trial: 24352094
Drug: Placebo (0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0% CHO) (700 mL)
Trial: 18246965
Drug: 9% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9% hydrogen peroxide gel (Colgate Visible White)
Trial: 18246965
Drug: 20% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% carbamide peroxide gel (Opalescence)
Trial: 11410799
Drug: 2 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 microg/kg G‐CSF (lenograstim) when grade 3 leukopenia or neutropenia appeared (Group 1)
Trial: 11410799
Drug: 4 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 microg/kg G‐CSF (lenograstim) when grade 3 leukopenia or neutropenia appeared (Group 2)
Trial: 11410799
Drug: 2 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 microg/kg G‐CSF (lenograstim) when grade 2 leukopenia or neutropenia appeared (Group 3)
Trial: 3113331
Drug: Ciprofloxacin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (250 mg) given twice a day for 2 days
Trial: 30881050
Drug: Iodixanol nasal
RxNorm normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodixanol nasal solution
Trial: 22766389
Drug: Glucose drink
RxNorm normalized name: Dextrose 15 GM Oral Solution [RELION GLUCOSE DRINK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose drink (25 g)
Trial: 22766389
Drug: Placebo drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drink (30 mg saccharine)
Trial: 12721240
Drug: Glutamine (4
RxNorm normalized name: N5-((2E)-((2-(((2,3-bis(omega-methoxypoly(oxyethylene))propoxy)carbonyl)amino)ethoxy)imino)ethyl)glutamine (43000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (4 g orally, twice a day for 2 weeks)
Trial: 12721240
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 g orally, twice a day for 2 weeks)
Trial: 8649495
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy and autologous bone marrow transplantation
Trial: 6299503
Drug: Combined pelvic
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined pelvic x-ray therapy plus a perineal proton beam boost (500 to 700 cGy dose to prostatic tumor)
Trial: 6299503
Drug: Conventional pelvic
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pelvic megavoltage x-ray therapy
Trial: 26860023
Drug: 20.25 mg
RxNorm normalized name: testosterone 20.25 MG/ACTUAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20.25 mg of hyperbaric ropivacaine in 5% dextrose (group B)
Trial: 26860023
Drug: 20.25 mg
RxNorm normalized name: testosterone 20.25 MG/ACTUAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20.25 mg of plain ropivacaine (group A)
Trial: 22512265
Drug: Glibenclamide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (5 mg/day)
Trial: 21163558
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (sesame oil + glibenclamide)
Trial: 15638906
Drug: Vardenafil 20
RxNorm normalized name: vardenafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil 20 mg
Trial: 12170362
Drug: High-dose methyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methyl prednisolone (30 mg/kg)
Trial: 12170362
Drug: Low-dose methyl
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methyl prednisolone (2 mg/kg)
Trial: 10660865
Drug: Inosine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inosine supplementation (10,000 mg.d‐1)
Trial: 7749832
Drug: Warfarin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin treatment with INR < 1.7
Trial: 7749832
Drug: Warfarin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin treatment with INR 1.7 to 2.5
Trial: 7749832
Drug: Warfarin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin treatment with INR > 2.5
Trial: 7749832
Drug: Warfarin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin treatment (general)
Trial: 7749832
Drug: Warfarin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin treatment in patients with congenital antithrombin III or protein C deficiency
Trial: 7749832
Drug: Warfarin discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin discontinuation in one patient
Trial: 7461761
Drug: PPD-G
RxNorm normalized name: Purified Protein Derivative - Tuberculin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPD-G
Trial: 29401082
Drug: Delayed initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Delayed initiation of oral feeding (1 week later)
Trial: 29401082
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (started oral feeding when physiologically stable)
Trial: 15671185
Drug: Enhanced care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced care (active treatment with practice nurses for 24 months)
Trial: 12791219
Drug: Analgesics administered
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics administered before surgical evaluation
Trial: 10496260
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) carbidopa/levodopa
Trial: 10496260
Drug: Controlled-release (CR)
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release (CR) carbidopa/levodopa
Trial: 7793557
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% 20 ml applied locally to the knee at the end of the procedure (n = 30)
Trial: 7793557
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg intramuscularly (n = 30)
Trial: 1771701
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg trospium chloride twice daily for 3 weeks
Trial: 7044532
Drug: Doxorubicin chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin chemotherapy with radiation therapy